



### **About IMI ND4BB Program**

Antibiotic-resistant bacteria kill 25 000 people in the EU every year, and cost the economy €1.5 billion. The Innovative Medicines Initiative (IMI) New Drugs 4 Bad Bugs (ND4BB) program has been launched to stimulate antibiotic development in Europe. ND4BB represents an unprecedented partnership between industry, academia and biotech organizations to combat antibiotic resistance in Europe by tackling the scientific, regulatory, and business challenges that are hampering the development of new antibiotics. For more information on IMI and the ND4BB program, please visit [www.imi.europa.eu](http://www.imi.europa.eu).

### **COMBACTE: improving clinical trials for antibiotics**

The COMBACTE project focusses on addressing the barriers to clinical development of new drugs in the ant-infections field. One of the key outcomes will be a high quality European clinical trial and laboratory network in which new antibiotics for treatment and prevention of infections caused by antibiotic-resistant bacteria can be evaluated. For more information on COMBACTE and the ASPIRE-ICU trial please visit [www.combacte.com](http://www.combacte.com).



This research project receives support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115523 | 115620 | 115737 resources of which are composed of financial contribution from the European Union Seventh Framework Programme (FP7/2007-2013) and EFPIA companies in kind contribution.